Induction of peripheral effector CD8 T-cell proliferation by combination of paclitaxel, carboplatin, and bevacizumab in non-small cell lung cancer patients
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
PURPOSE: Chemotherapy has long been the standard treatment for advanced stage non-small cell lung cancer (NSCLC), but checkpoint inhibitors are now approved for use in several patient groups and combinations. To design optimal combination strategies, a better understanding of the immune-modulatory capacities of conventional treatments is needed. Therefore, we investigated the immune-modulatory effects of paclitaxel/carboplatin/bevacizumab (PCB), focusing on the immune populations associated with the response to checkpoint inhibitors in peripheral blood. EXPERIMENTAL DESIGN: A total of 223 patients with stage IV NSCLC, enrolled in the NVALT12 study, received PCB, with or without nitroglycerin patch. Peripheral blood was collected at baseline and after the first and second treatment cycle, proportions of T cells, B cells, and monocytes were determined by flow cytometry. Furthermore, several subsets of T cells and the expression of Ki67 and coinhibitory receptors on these subsets were determined. RESULTS: effector subsets. The proliferating CD8 T cells more highly expressed programmed death receptor (PD)-1 and cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) compared with nonproliferating CD8 T cells. Immunologic responders (iR; >2 fold increased proliferation after treatment) did not show an improved progression-free (PFS) or overall survival (OS). CONCLUSIONS: Paclitaxel/carboplatin/bevacizumab induces proliferation of CD8 T cells, consisting of effector cells expressing coinhibitory checkpoint molecules. Induction of proliferation was not correlated to clinical outcome in the current clinical setting. Our findings provide a rationale for combining PCB with checkpoint inhibition in lung cancer.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The text we found for this paper looks like another document, so the self-check wasn’t run.
Citations
Cites
Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D. M., Forman, D., & Bray, F. (2015) · International Journal of Cancer · doi:10.1002/ijc.29210 · Cited by 28,766
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089 · cited 7×
“For first-line treatment in NSCLC, pembrolizumab is FDA-approved as single treatment for patients with >50% PD-L1–positive tumor cells and in combination with pemetrexed/carboplatin for nonsquamous NSCLC regardless of PD-L1 status (7, 8).”
BackgroundInfluentialHerbst, R. S., Baas, P., Kim, D.-W., Felip, E., Pérez-Gracia, J. L., Han, J.-Y., Molina, J., Kim, J.-H., Arvis, C. D., Ahn, M.-J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01281-7 · Cited by 6,449
Elements of cancer immunity and the cancer–immune set point
Chen, D. S., & Mellman, I. (2017) · Nature · doi:10.1038/nature21349 · Cited by 5,352 · cited 1×
“This would be supported by the reported finding that T cells with intermediate PD1 expression are most sensitive to anti-PD-1 treatment (25).”
ResultDurvalumab after chemoradiotherapy in stage III non–small-cell lung cancer
Antonia, S. J., Villegas, A., Daniel, D., Vicente, D., Murakami, S., Hui, R., Yokoi, T., Chiappori, A., Lee, K. H., de Wit, M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709937 · Cited by 4,593
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
Socinski, M. A., Jotte, R. M., Cappuzzo, F., Orlandi, F., Stroyakovskiy, D., Nogami, N., Rodríguez-Abreu, D., Moro-Sibilot, D., Thomas, C. A., Barlesi, F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716948 · Cited by 3,733 · cited 2×
“Here, combined treatment of atezolizumab with paclitaxel/ carboplatin/bevacizumab (PCB) performed better than PCB alone and was FDA-approved recently (9).”
MethodT-cell invigoration to tumour burden ratio associated with anti-PD-1 response
Huang, A. C., Postow, M. A., Orlowski, R. J., Mick, R., Bengsch, B., Manne, S., Xu, W., Harmon, S., Giles, J. R., Wenz, B., et al. (2017) · Nature · doi:10.1038/nature22079 · Cited by 1,664 · cited 6×
“In this context, it is of note that it was reported that in response to checkpoint inhibition, Ki67þCD8T cells peaked after 3or 6weeks in most patients (13).”
BackgroundInfluentialImmunological effects of conventional chemotherapy and targeted anticancer agents
Galluzzi, L., Buqué, A., Kepp, O., Zitvogel, L., & Kroemer, G. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.10.012 · Cited by 1,530 · cited 1×
“Indeed, variable effects on several immune cell populations have been described for different chemotherapeutic treatments, as reviewed by Galuzzi and colleagues (11).”
BackgroundLanger, C. J., Gadgeel, S. M., Borghaei, H., Papadimitrakopoulou, V. A., Patnaik, A., Powell, S. F., Gentzler, R. D., Martins, R. G., Stevenson, J. P., Jalal, S. I., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30498-3 · Cited by 1,404 · cited 1×
“For first-line treatment in NSCLC, pembrolizumab is FDA-approved as single treatment for patients with >50% PD-L1–positive tumor cells and in combination with pemetrexed/carboplatin for nonsquamous NSCLC regardless of PD-L1 status (7, 8).”
BackgroundImmunological hallmarks of stromal cells in the tumour microenvironment
Turley, S. J., Cremasco, V., & Astarita, J. L. (2015) · Nature Reviews Immunology · doi:10.1038/nri3902 · Cited by 1,140
Cited by
Immunomodulation by targeted anticancer agents
Petroni, G., Buqué, A., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2021) · Cancer Cell · doi:10.1016/j.ccell.2020.11.009 · Cited by 212
Targeting oncogene and non-oncogene addiction to inflame the tumour microenvironment
Petroni, G., Buqué, A., Coussens, L. M., & Galluzzi, L. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00415-5 · Cited by 160
Xie, X., Yang, Y., Wang, Q., Liu, H.-F., Fang, X., Li, C., Jiang, Y., Wang, S., Zhao, H., Miao, J., et al. (2023) · Cell Research · doi:10.1038/s41422-022-00766-z · Cited by 139
“However, the increased T cells express high levels of the immune inhibitory checkpoints PD-1 and CTLA-4 and fail to improve patient survival.(58) Moreover, a recent study reports that paclitaxel regimen may compromise the efficacy of anti-PD-L1 antibodies in chemoimmunotherapy by reducing antitumor immune cells and in…”
BackgroundThe interactions of paclitaxel with tumour microenvironment
Yu, D., Lou, Z., Ma, F.-Y., & Najafi, M. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.108555 · Cited by 102
Platinum Derivatives Effects on Anticancer Immune Response
Rébé, C., Demontoux, L., Pilot, T., & Ghiringhelli, F. (2019) · Biomolecules · doi:10.3390/biom10010013 · Cited by 79
Metadata
- Authors
- de Goeje, P. L., Poncin, M., Bezemer, K., Kaijen-Lambers, M. E. H., Groen, H. J. M., Smit, E. F., Dingemans, A.-M. C., Kunert, A., Hendriks, R. W., & Aerts, J. G. J. V.
- Affiliations
- 1Department of Pulmonary Medicine, Erasmus MC, Rotterdam, the Netherlands.
- Erasmus MC (NL)
- University Medical Center Groningen (NL)
- The Netherlands Cancer Institute (NL)
- Maastricht University Medical Centre (NL)
- ORCID
- Venue
- Clinical Cancer Research
- Published
- 2019-04-01
- Volume
- 25
- Issue
- 7
- Pages
- 2219-2227
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2910094802
- Cited by
- 43
- References
- 25
- Citations by year
- 2026: 2 · 2025: 7 · 2024: 5 · 2023: 6 · 2022: 11 · 2021: 7 · 2020: 3 · 2019: 2
- FWCI
- 2.40
- Type
- journal article
- Language
- en
- Open access
- green
- research.rug.nl
- Licence
- other-oa
- Locations
- Clinical Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (publishedVersion, other-oa)
- Research Publications (Maastricht University) (acceptedVersion, other-oa)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion)
- Research Publications (Maastricht University) (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Funders
- Stichting NVALT Studies
- KWF Kankerbestrijding (Dutch Cancer Society) (UM 2010-4883)
- Roche
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- non-small cell lung cancer, paclitaxel, carboplatin, bevacizumab, CD8+ T cell proliferation, immune checkpoint inhibitors, PD-1, CTLA-4, co-inhibitory receptors, nitroglycerin patch, immunomodulation, T cell subsets, Ki-67, progression-free survival, overall survival
- MeSH terms
- Bevacizumab, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung, Female, Humans, Lung Neoplasms, Lymphocyte Activation, Male, Prognosis, Biomarkers, Tumor, CD4-Positive T-Lymphocytes, Gene Expression, Immunophenotyping, Carboplatin, Treatment Outcome, Paclitaxel, CD8-Positive T-Lymphocytes, Lymphocyte Count, Cell Proliferation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Induction of peripheral effector CD8 T-cell proliferation by combination of paclitaxel, carboplatin, and bevacizumab in non-small cell lung cancer patients. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-18-2243
- The paper
- de Goeje, P. L., Poncin, M., Bezemer, K., Kaijen-Lambers, M. E. H., Groen, H. J. M., Smit, E. F., Dingemans, A.-M. C., Kunert, A., Hendriks, R. W., & Aerts, J. G. J. V. (2019). Induction of peripheral effector CD8 T-cell proliferation by combination of paclitaxel, carboplatin, and bevacizumab in non-small cell lung cancer patients. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-18-2243
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.